- Previous Close
14.52 - Open
14.46 - Bid --
- Ask --
- Day's Range
14.06 - 14.58 - 52 Week Range
14.06 - 25.84 - Volume
1,174 - Avg. Volume
11,094 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
0.10 - EPS (TTM)
1.50 - Earnings Date Mar 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
www.polypeptide.com1,362
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0AAJ.L
View MorePerformance Overview: 0AAJ.L
Trailing total returns as of 4/13/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0AAJ.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0AAJ.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.81%
Return on Assets (ttm)
-0.51%
Return on Equity (ttm)
-5.30%
Revenue (ttm)
336.79M
Net Income Avi to Common (ttm)
-19.56M
Diluted EPS (ttm)
1.50
Balance Sheet and Cash Flow
Total Cash (mrq)
68.28M
Total Debt/Equity (mrq)
29.36%
Levered Free Cash Flow (ttm)
-67.96M